The Korean Journal of Pain

The Korean Pain Society (대한통증학회)
권호 표지
DOI QR코드

DOI QR Code

Recombinant zoster vaccine (Shingrix®): a new option for the prevention of herpes zoster and postherpetic neuralgia

  • Singh, Grisuna (Department of Anesthesiology and Intensive Care, Nepalgunj Medical College and Teaching Hospital) ;
  • Song, Sejin (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Choi, Eunjoo (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Lee, Pyung-Bok (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital) ;
  • Nahm, Francis Sahngun (Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital)
  • Received : 2020.03.05
  • Accepted : 2020.04.16
  • Published : 2020.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

Postherpetic neuralgia (PHN) is a challenging condition for pain management specialists. The prevention of herpes zoster (HZ) and subsequent PHN in individuals aged 50 years and older, via the development of new vaccines, is an ongoing research project. The live zoster vaccine (LZV, Zostavax®) was the first proof of concept that vaccination could prevent HZ, but LZV cannot be used in various immunecompromised patients. This led to the development of a new non-live recombinant zoster vaccine (RZV, Shingrix®). This RZV has shown promising results in many clinical trials, with high reactogenicity and similar systemic adverse effects compared to those of LZV. The National Advisory Committee on Immunization has recommended LZV as a standard vaccine for HZ prevention in adults ≥ 50 years of age, but no studies directly comparing the safety and efficacy of RZV and LZV vaccines have been conducted. This article reviews the brief history, efficacy, and safety of the two vaccines and discusses the advantage of RZV over LZV based on the available literature.

Keywords

References

  1. Jeon YH. Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment. Korean J Pain 2015; 28: 177-84. https://doi.org/10.3344/kjp.2015.28.3.177
  2. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342: 635-45. https://doi.org/10.1056/NEJM200003023420906
  3. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014; 371: 1526-33. https://doi.org/10.1056/NEJMcp1403062
  4. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, et al. Varicella zoster virus infection. Nat Rev Dis Primers 2015; 1: 15016. https://doi.org/10.1038/nrdp.2015.16
  5. Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain 2018; 31: 235-43. https://doi.org/10.3344/kjp.2018.31.4.235
  6. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011; 52: 332-40. https://doi.org/10.1093/cid/ciq077
  7. Chernev I, Gomez E. Herpes zoster and diabetes mellitus. Korean J Pain 2014; 27: 92. https://doi.org/10.3344/kjp.2014.27.1.92
  8. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356: 1338-43. https://doi.org/10.1056/NEJMct066061
  9. Hong MJ, Kim YD, Cheong YK, Park SJ, Choi SW, Hong HJ. Epidemiology of postherpetic neuralgia in Korea: an electronic population health insurance system based study. Medicine (Baltimore) 2016; 95: e3304. https://doi.org/10.1097/md.0000000000003304
  10. Kim KH. Herpes zoster vaccination. Korean J Pain 2013; 26: 242-8. https://doi.org/10.3344/kjp.2013.26.3.242
  11. Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016; 375: 1019-32. https://doi.org/10.1056/NEJMoa1603800
  12. Weller TH, Witton HM, Bell EJ. The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro. J Exp Med 1958; 108: 843-68. https://doi.org/10.1084/jem.108.6.843
  13. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2: 1288-90.
  14. Wang L, Zhu L, Zhu H. Efficacy of varicella (VZV) vaccination: an update for the clinician. Ther Adv Vaccines 2016; 4: 20-31. https://doi.org/10.1177/2051013616655980
  15. Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010; 27: 159-76. https://doi.org/10.2165/10489140-000000000-00000
  16. Syed YY. Recombinant zoster vaccine ($(Shingrix^{(R)})$): a review in herpes zoster. Drugs Aging 2018; 35: 1031-40. https://doi.org/10.1007/s40266-018-0603-x
  17. Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and posthoc efficacy analysis. Lancet Infect Dis 2019; 19: 988-1000. https://doi.org/10.1016/S1473-3099(19)30163-X
  18. Warrington R, Ismail S; National Advisory Committee on Immunization (NACI). Summary of the NACI update on herpes zoster vaccines. Can Commun Dis Rep 2018; 44: 220-5. https://doi.org/10.14745/ccdr.v44i09a06
  19. Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, et al. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis 2019; 19: 1001-12. https://doi.org/10.1016/S1473-3099(19)30310-X
  20. Eberhardson M, Hall S, Papp KA, Sterling TM, Stek JE, Pang L, et al. Safety and immunogenicity of inactivated varicellazoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind, placebo-controlled clinical trial. Clin Infect Dis 2017; 65: 1174-82. https://doi.org/10.1093/cid/cix484
  21. Parrino J, McNeil SA, Lawrence SJ, Kimby E, Pagnoni MF, Stek JE, et al. Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine 2017; 35: 1764-9. https://doi.org/10.1016/j.vaccine.2016.10.055
  22. Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197(Suppl 2): S237-41. https://doi.org/10.1086/522129
  23. Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines 2018; 17: 619-34. https://doi.org/10.1080/14760584.2018.1495565
  24. Choi WS. Herpes zoster vaccine in Korea. Clin Exp Vaccine Res 2013; 2: 92-6. https://doi.org/10.7774/cevr.2013.2.2.92
  25. Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54: 922-8. https://doi.org/10.1093/cid/cir970
  26. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84. https://doi.org/10.1056/NEJMoa051016
  27. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012; 55: 1320-8. https://doi.org/10.1093/cid/cis638
  28. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60: 900-9. https://doi.org/10.1093/cid/ciu918
  29. Tseng HF, Harpaz R, Luo Y, Hales CM, Sy LS, Tartof SY, et al. Declining effectiveness of herpes zoster vaccine in adults aged ${\geq}$60 years. J Infect Dis 2016; 213: 1872-5. https://doi.org/10.1093/infdis/jiw047
  30. Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol 2018; 187: 161-9. https://doi.org/10.1093/aje/kwx245
  31. Zussman J, Young L. Zoster vaccine live for the prevention of shingles in the elderly patient. Clin Interv Aging 2008; 3: 241-50. https://doi.org/10.2147/CIA.S1225
  32. Didierlaurent AM, Laupeze B, Di Pasquale A, Hergli N, Collignon C, Garcon N. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 2017; 16: 55-63. https://doi.org/10.1080/14760584.2016.1213632
  33. Berarducci B, Ikoma M, Stamatis S, Sommer M, Grose C, Arvin AM. Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol 2006; 80: 9481-96. https://doi.org/10.1128/JVI.00533-06
  34. Symoniak MR, Farrokh P, Gandhi MA, Slish JC. Herpes zoster subunit vaccine for the prevention of herpes zoster. Am J Health Syst Pharm 2018; 75: 861-9. https://doi.org/10.2146/ajhp170399
  35. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372: 2087-96. https://doi.org/10.1056/NEJMoa1501184
  36. Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 2018; 14: 1370-7. https://doi.org/10.1080/21645515.2018.1442162
  37. Lopez-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine 2019; 37: 2482-93. https://doi.org/10.1016/j.vaccine.2019.03.043
  38. McGirr A, Widenmaier R, Curran D, Espie E, Mrkvan T, Oostvogels L, et al. The comparative efficacy and safety of herpes zoster vaccines: a network meta-analysis. Vaccine 2019; 37: 2896-909. https://doi.org/10.1016/j.vaccine.2019.04.014
  39. Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis 2017; 216: 1343-51. https://doi.org/10.1093/infdis/jix482
  40. Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep 2018; 67: 103-8. https://doi.org/10.15585/mmwr.mm6703a5
  41. German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI). Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017; 60: 1162-79. https://doi.org/10.1007/s00103-017-2618-6
  42. Siedler A, Koch J, Garbe E, Hengel H, von Kries R, Ledig T, et al. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine: statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62: 352-76. https://doi.org/10.1007/s00103-019-02882-5
  43. Gabutti G, Bolognesi N, Sandri F, Florescu C, Stefanati A. Varicella zoster virus vaccines: an update. Immunotargets Ther 2019; 8: 15-28. https://doi.org/10.2147/ITT.S176383